InvAscent
- Company typePrivate
- Founded2005
- HeadquartersHyderabad, India
- Headcount11–50
- GTM typeB2B
- OfferingServices
What InvAscent does
InvAscent is a Hyderabad-headquartered private equity firm founded in 2005 that operates as the investment manager to the India Life Sciences Fund (ILSF) family of SEBI-registered Category II Alternative Investment Funds. The firm invests growth equity exclusively in the Indian life sciences sector — spanning pharmaceutical manufacturing (APIs, formulations, CDMOs such as Maiva Pharma), healthcare delivery (hospital chains such as Apex, SRV, Ankura, Sunshine, HCG; specialty care such as Geri Care), medical devices, animal health, nutraceuticals/specialty ingredients, and select HealthTech (ABI Health). Across four fund vintages, InvAscent has made 39 investments and achieved 20 realizations, with assets under management exceeding USD 850 million.
The firm's core "products" are the four ILSF fund vintages, with Fund IV (closed at USD 304 million in 2023–2024, targeting USD 400 million including co-investments) being the largest and the first to draw one-third of its LP base from Indian institutional investors. The firm differentiates itself through a specialist team that combines investing credentials with operating experience in pharmaceuticals and healthcare delivery — including alumni of McKinsey, Abbott Laboratories, Apollo Hospitals, Dr. Reddy's Laboratories, Jubilant Life Sciences, and major global investment banks — enabling a "collaborative partnership" model in which InvAscent provides growth capital alongside strategic guidance, business development support, corporate finance advice, and corporate governance improvements.
InvAscent generates revenue through three primary streams: recurring management fees charged to limited partners of the ILSF fund family, performance-based carried interest on successful exits (notably 4x returns on Apex Hospitals and IPO exits including HCG on BSE and Gland Pharma on NSE), and capital gains realized through exits via IPOs, strategic sales, and secondary transactions. The firm operates from offices in Hyderabad (headquarters), Mumbai, and Gandhinagar, and is regulated by SEBI with Axis Trustee Services Limited acting as trustee to Fund IV. Recent strategic activity includes INR 10,000 million deployment into Maiva Pharma alongside Morgan Stanley PE Asia, INR 2,300 million into Apex Hospitals (including a full secondary buyout from Somerset Indus), and a USD 10 million HealthTech position in ABI Health Technologies.
InvAscent firmographics
Firmographics- Name
- InvAscent
- Legal name
- ILSF Lifesciences Manager LLP
- Website
- https://invascent.com
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
InvAscent industry classification
Industry- Product category
- Private Equity (Life Sciences)
- NAICS
- Portfolio Management and Investment Advice (523940), Other Financial Investment Activities (5239), All Other Financial Investment Activities (52399)
- SIC
- Investment Advice (6282), Security Brokers, Dealers & Flotation Companies (6211)
- akta.pro primary industry
- Healthcare & Life Sciences Growth Equity (FSANACAB)
- akta.pro secondary industries
- Equity Capital Advisory (Private Equity Placements, Growth Capital) (BPAHAOAE), Capital Raising Advisory (Debt/Equity/Private Capital) (BPAHADAG)
Keywords
Where InvAscent is headquartered
LocationHeadquarters
- HQ city
- Hyderabad
- HQ country
- India
- HQ region
- Asia
Offices3 records
Markets served
InvAscent business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Others
Revenue model
- Management Fees: Private equity fund management fees charged to limited partners for managing the India Life Sciences Fund family of funds.
- Carried Interest / Performance Fees: Performance-based carried interest from successful exits and value creation in portfolio companies across Fund I through Fund IV.
- Capital Gains: Realization of equity gains through exits of portfolio companies including IPOs, strategic sales, and secondary transactions.
Distribution channels1 record
Marketing channels1 record
InvAscent product offering
Product offeringCore offering
InvAscent provides growth equity capital to small and mid-sized Indian life sciences companies through a family of four SEBI-registered Category II Alternative Investment Funds (India Life Sciences Funds I through IV) with over USD 850 million in assets under management. The firm invests across pharmaceuticals, healthcare delivery, medical devices, animal health, nutraceuticals, and healthtech, supplementing capital with strategic guidance, business development support, corporate finance advice, and corporate governance improvement under a collaborative partnership model. Since inception in 2005, the firm has executed 39 investments and 20 exits, generating over 4x EBITDA increase across portfolio companies.
Product overview
InvAscent is India’s leading life sciences private equity firm offering a family of four investment funds (India Life Sciences Funds I through IV) with USD 850+ million in assets under management. The firm deploys a collaborative partnership model to co-create sustained value in portfolio companies across pharmaceuticals, healthcare delivery, medical devices, animal health, specialty ingredients, and healthtech. With 39 investments and 20 exits since inception, the funds target small and mid-sized businesses requiring growth capital in India's life sciences sector, providing not only funding but also strategic guidance, business development assistance, and corporate finance advisory services.
Differentiator
Problem solved
Functional benefit
Products and services
- India Life Sciences Fund IV (ILSF IV) SEBI-registered Category II Alternative Investment Fund targeting growth equity investments in Indian life sciences companies across pharmaceuticals, healthcare delivery, medical devices, animal health, nutraceuticals, and healthtech sectors. Aimed at institutional limited partners.
- India Life Sciences Fund III (ILSF III) Third fund in the India Life Sciences Fund series with portfolio investments including Ankura, Malladi Drugs, Symbiotec Pharmalab, and Medibuddy across healthcare delivery and pharmaceutical sectors. Aimed at institutional limited partners.
- India Life Sciences Fund II (ILSF II) Second fund in the India Life Sciences Fund series with 12 portfolio investments including Aizant, Alniche, Biorad, Oasis Fertility, Oliva, and Sunshine Hospitals. Aimed at institutional limited partners.
- India Life Sciences Fund I (ILSF I) First fund in the India Life Sciences Fund series, fully realised with 8 investments including Anjan Drugs, Dr. Agarwal's Health Care, Fermenta Biotech, Gland Pharma, HCG, Neuland Group, Sutures India, and Uquifa. Aimed at institutional limited partners.
- Growth Equity Investment Services Collaborative partnership model delivering growth equity capital alongside strategic guidance, business development assistance, corporate finance advice, and corporate governance recommendations to portfolio companies in the Indian life sciences sector. Aimed at entrepreneur-led small and mid-sized life sciences businesses.
Quantifiable outcome
- Over 4-fold increase in EBITDA across portfolio companies
- +2 more outcomes
Companies that use InvAscent
Customer profileSegments7 records
Ideal customer profiles2 records
InvAscent technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
InvAscent partnerships and signals
Strategic signalScale indicators9 records
Recent moves6 records
Expansion highlights6 records
InvAscent competitors and assessment
Company assessmentDirect peers
- Somerset Indus Capital Partners: Somerset Indus Capital Partners is an India-focused growth equity firm investing in healthcare and consumer businesses. It is the most direct peer — InvAscent acquired Somerset's stake in Apex Hospitals in 2025, evidencing head-to-head competition for the same mid-market healthcare deals.
- Quadria Capital: Quadria Capital is one of Asia's largest healthcare-focused private equity firms, deploying growth capital across pharma, hospitals, medtech, and diagnostics in South and Southeast Asia. It competes with InvAscent on virtually the same mid-market Indian healthcare deals.
- HealthQuad: HealthQuad is an Indian venture/growth fund dedicated to healthcare, investing across pharma, medical devices, digital health, and healthcare delivery. It overlaps with InvAscent's Fund IV HealthTech and hospital delivery mandates (e.g., MediBuddy, ABI Health).
- Tata Capital Healthcare Fund: Tata Capital's healthcare fund invests growth equity across Indian pharma, hospitals, and medical devices. Henal Agrawal previously worked there, indicating direct talent and deal overlap with InvAscent's portfolio.
- Asian Healthcare Fund: Asian Healthcare Fund is a healthcare-focused PE/VC investor operating in India. Its pharma and hospital delivery theses overlap directly with InvAscent's ILSF mandate.
Broad incumbents
- ChrysCapital: ChrysCapital is one of India's largest homegrown PE firms with healthcare exposure (e.g., Mankind Pharma) across multiple funds. While multi-sector, it competes for mid-market healthcare growth equity checks and serves similar LPs.
- Kedaara Capital: Kedaara Capital is an India-focused PE firm with healthcare investments (e.g., IndiaFirst Life, hospital platforms). A generalist with deep sector overlap that competes for similar growth equity tickets in Indian healthcare.
- Multiples Alternate Asset Management: Multiples is a large Indian PE firm with healthcare exposure across its funds. It targets similar growth-stage Indian companies and competes in adjacent deal flow to InvAscent's specialty pharma and hospital mandates.
- Everstone Capital: Everstone is a Singapore-headquartered PE firm with significant Indian healthcare exposure. Its pan-Asia reach and larger fund sizes position it as a competitor and potential co-investor alongside InvAscent.
Emerging players
- Norwest Venture Partners: Norwest Venture Partners India invests growth capital into healthcare and tech-enabled health services. It overlaps with InvAscent's HealthTech/healthcare delivery theses, particularly in digital health and consumer-facing care platforms.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
InvAscent social profiles
Digital presenceInvAscent compliance and trust
Trust signalCompliance2 records
InvAscent financial estimates
Financial estimateRevenue estimate
Valuation estimate
InvAscent leadership team
Management profileNumber of profiles
Profiles16 records
InvAscent funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
InvAscent M&A and investment
M&A and investmentM&A
Investments34 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about InvAscent
What does InvAscent do?
InvAscent provides growth equity capital to small and mid-sized Indian life sciences companies through a family of four SEBI-registered Category II Alternative Investment Funds (India Life Sciences Funds I through IV) with over USD 850 million in assets under management. The firm invests across pharmaceuticals, healthcare delivery, medical devices, animal health, nutraceuticals, and healthtech, supplementing capital with strategic guidance, business development support, corporate finance advice, and corporate governance improvement under a collaborative partnership model. Since inception in 2005, the firm has executed 39 investments and 20 exits, generating over 4x EBITDA increase across portfolio companies.
Is InvAscent a public or private company?
InvAscent is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was InvAscent founded?
InvAscent was founded in 2005. It employs 11 to 50 people.
Where is InvAscent based?
InvAscent is headquartered in Hyderabad, India, in the Asia region.
How does InvAscent make money?
Three revenue lines are on record. Management Fees are the primary driver. The others are carried Interest / Performance Fees and capital Gains.
Who are InvAscent's main competitors?
Direct peers on record are Somerset Indus Capital Partners, Quadria Capital, HealthQuad, Tata Capital Healthcare Fund and Asian Healthcare Fund. Broad incumbents are ChrysCapital, Kedaara Capital, Multiples Alternate Asset Management and Everstone Capital. Norwest Venture Partners is listed as an emerging player.
Does InvAscent have an API?
No public API is recorded for InvAscent.
What industry is InvAscent in?
InvAscent's product category is Private Equity (Life Sciences). Its primary akta.pro industry code is FSANACAB, Healthcare & Life Sciences Growth Equity, with a secondary code of BPAHAOAE, Equity Capital Advisory (Private Equity Placements, Growth Capital). Its NAICS code is 523940 and its SIC code is 6282.